Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Series Introduction: COX in a crystal ball: current status and future promise of prostaglandin research
Garret A. FitzGerald, Patrick Loll
Garret A. FitzGerald, Patrick Loll
View: Text | PDF
Perspective

Series Introduction: COX in a crystal ball: current status and future promise of prostaglandin research

  • Text
  • PDF
Abstract

Authors

Garret A. FitzGerald, Patrick Loll

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Isoform-selective inhibitor binding. The COX-1 and COX-2 active sites ar...
Isoform-selective inhibitor binding. The COX-1 and COX-2 active sites are shown superimposed (COX-1, yellow; COX-2, pink). Two inhibitors are seen: flurbiprofen (orange), a nonselective inhibitor, and SC-558 (blue), a COX-2–selective inhibitor. NSAIDs achieve COX inhibition by occupying the upper portion of the active site channel, preventing the fatty acid substrate from gaining access to the active site tyrosine seen at the upper right. Note how the COX-2–selective inhibitor projects leftward into a side pocket that is not exploited by the nonselective inhibitor.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts